Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib in IDH1/2 Mutant Advanced Solid Tumors
NCT03212274Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2019
- Primary completion
- Apr 2025
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in glioma, cholangiocarcinoma (CCA), solid tumor, sponsored by National Cancer Institute. Started Jan 2019; status: active, not recruiting.
02
Drugs
olaparib
03
Conditions
gliomacholangiocarcinoma (CCA)solid tumor
Beyond the preview
Go deeper on NCT03212274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03212274.